Physical Examination clinical trials

Explore recruiting physical examination clinical trials.

Recruiting physical examination studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Physical Examination trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy

Italy, Spain, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Spain, Italy, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study of CMP-CPS-001 in Healthy Volunteers and Participants with Abnormal Heterozygous Ornithine Transcarbamylase (OTC) Genotype

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

Greece, Spain, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Hungary, Austria, Germany, France, Spain, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Physical Examination trials by city

Physical Examination in Toronto Physical Examination in Vancouver Physical Examination in Montreal Physical Examination in Calgary Physical Examination in Edmonton Physical Examination in Ottawa Physical Examination in Winnipeg Physical Examination in Quebec City Physical Examination in Hamilton Physical Examination in Kitchener Physical Examination in London Physical Examination in Halifax Physical Examination in New York Physical Examination in Los Angeles Physical Examination in Chicago Physical Examination in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease